Jaspreet Jaggi, M.D., Ph.D. joined BeiGene in 2020 as Senior Vice President and Head, Clinical Portfolio Strategy.

Prior to joining BeiGene, Dr. Jaggi served in various leadership roles in clinical evaluation and clinical development for Novartis over some 10 years. Most recently, as Vice President and Global Head of Oncology Clinical Evaluation, he led the scientific and strategic evaluation for both the internal oncology pipeline and external innovation. Additionally, he spearheaded the scientific and clinical evaluation of business development opportunities, including the acquisitions of GSK Oncology, AAA, Endocyte, CoStim, and Admune, as well as strategic investments in CAR-T therapy and various in-licensing agreements. Dr. Jaggi also served as Global Clinical Program Head for Oncology Biosimilars, overseeing an integrated clinical development team across Sandoz and Novartis. Prior to Novartis, he served in various clinical development roles at Bristol Myers Squib and Pfizer.

Dr. Jaggi received his medical degree from Grant Medical College in Mumbai, India, and a Ph.D. in pharmacology from the Weill Cornell Medical College/Memorial Sloan Kettering joint program. He was a Ludwig Center for Cancer Immunotherapy fellow at Memorial Sloan Kettering Cancer Center.